vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Third Coast Bancshares, Inc. (TCBX). Click either name above to swap in a different company.
Third Coast Bancshares, Inc. is the larger business by last-quarter revenue ($57.7M vs $57.3M, roughly 1.0× RHYTHM PHARMACEUTICALS, INC.). Third Coast Bancshares, Inc. runs the higher net margin — 28.4% vs -83.0%, a 111.4% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 17.5%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
RYTM vs TCBX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $57.7M |
| Net Profit | $-47.5M | $16.4M |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | — |
| Net Margin | -83.0% | 28.4% |
| Revenue YoY | 36.9% | — |
| Net Profit YoY | -9.6% | 20.5% |
| EPS (diluted) | $-0.73 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $57.7M | ||
| Q4 25 | $57.3M | $56.5M | ||
| Q3 25 | $51.3M | $54.5M | ||
| Q2 25 | $48.5M | $52.0M | ||
| Q1 25 | $32.7M | $45.9M | ||
| Q4 24 | $41.8M | $46.3M | ||
| Q3 24 | $33.3M | $42.9M | ||
| Q2 24 | $29.1M | $41.7M |
| Q1 26 | — | $16.4M | ||
| Q4 25 | $-47.5M | $17.9M | ||
| Q3 25 | $-52.9M | $18.1M | ||
| Q2 25 | $-46.6M | $16.7M | ||
| Q1 25 | $-49.5M | $13.6M | ||
| Q4 24 | $-43.3M | $13.7M | ||
| Q3 24 | $-43.6M | $12.8M | ||
| Q2 24 | $-32.3M | $10.8M |
| Q1 26 | — | — | ||
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 88.6% | — | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | -82.2% | 38.1% | ||
| Q3 25 | -102.6% | 41.9% | ||
| Q2 25 | -93.4% | 40.5% | ||
| Q1 25 | -143.7% | 37.8% | ||
| Q4 24 | -98.6% | 38.7% | ||
| Q3 24 | -132.0% | 37.9% | ||
| Q2 24 | -139.2% | 34.1% |
| Q1 26 | — | 28.4% | ||
| Q4 25 | -83.0% | 31.7% | ||
| Q3 25 | -103.1% | 33.1% | ||
| Q2 25 | -96.1% | 32.2% | ||
| Q1 25 | -151.4% | 29.6% | ||
| Q4 24 | -103.6% | 29.7% | ||
| Q3 24 | -131.2% | 29.8% | ||
| Q2 24 | -110.9% | 25.9% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-0.73 | $1.02 | ||
| Q3 25 | $-0.82 | $1.03 | ||
| Q2 25 | $-0.75 | $0.96 | ||
| Q1 25 | $-0.81 | $0.78 | ||
| Q4 24 | $-0.71 | $0.80 | ||
| Q3 24 | $-0.73 | $0.74 | ||
| Q2 24 | $-0.55 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $650.5M |
| Total Assets | $480.2M | $6.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $388.9M | $175.2M | ||
| Q3 25 | $416.1M | $116.4M | ||
| Q2 25 | $291.0M | $113.1M | ||
| Q1 25 | $314.5M | $219.0M | ||
| Q4 24 | $320.6M | $371.2M | ||
| Q3 24 | $298.4M | $258.2M | ||
| Q2 24 | $319.1M | $241.8M |
| Q1 26 | — | $650.5M | ||
| Q4 25 | $139.1M | $531.0M | ||
| Q3 25 | $148.8M | $513.8M | ||
| Q2 25 | $-11.9M | $496.1M | ||
| Q1 25 | $18.9M | $479.8M | ||
| Q4 24 | $21.7M | $460.7M | ||
| Q3 24 | $11.2M | $450.5M | ||
| Q2 24 | $39.3M | $435.0M |
| Q1 26 | — | $6.6B | ||
| Q4 25 | $480.2M | $5.3B | ||
| Q3 25 | $506.9M | $5.1B | ||
| Q2 25 | $372.7M | $4.9B | ||
| Q1 25 | $386.7M | $4.9B | ||
| Q4 24 | $392.3M | $4.9B | ||
| Q3 24 | $363.6M | $4.6B | ||
| Q2 24 | $381.8M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-25.4M | $50.8M | ||
| Q3 25 | $-26.6M | $20.7M | ||
| Q2 25 | $-23.3M | $13.9M | ||
| Q1 25 | $-40.4M | $10.5M | ||
| Q4 24 | $-18.8M | $35.1M | ||
| Q3 24 | $-25.2M | $22.0M | ||
| Q2 24 | $-29.1M | $7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.84× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | 2.56× | ||
| Q3 24 | — | 1.72× | ||
| Q2 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
